Influenza Diagnostics and Respiratory Protection

Julie Schafer, PhD, MPH, MS
Director of Strategy (Acting)
October 29, 2018
BARDA Influenza Diagnostics Program Strategy

- **Goal:** *Early identification of influenza for early action*
- **Empowering the individual by bringing diagnostics into the home*
**Home Collection of Specimens**

**Rapid Influenza Diagnosis**

- Nasal Swab Home-Collection Kit
- FDA-cleared Sofia2 FIA Analyzer
- Located at Urgent Care Centers or Pharmacies
- Provides positive Influenza A or B results in a quickly as 3 minutes and negative results in 15 minutes

**Advances in Sample Collection:**

- Eliminate invasive nasopharyngeal swab
- Professional and home use versions

**Aardvark Medical ClearinseCTS™**
Home Influenza Testing: Cue Health, Inc & Diassess, Inc

- Nucleic-acid Amplification test (NAAT)
- Rapid (<25 minutes)
- Sensitive and specific molecular platform

Innovating for the Next Pandemic: Reimagining Respiratory Protection

- All ages & populations
- SIMPLE
- NO Fit Testing
- Prevents Infection
- Minimally interfering
- Comfortable
- Reusable

= ?

ASPR
BARD
How to contact BARDA

**Medical Countermeasures.gov**
Portal to BARDA: Register to request a TechWatch meeting!

**www.fbo.gov/** ("FedBizOpps")
Official announcements and info for all government contract solicitations

**https://www.phe.gov/about/**
BARDA/Pages/default.aspx
Program description, information, news, announcements

**www.drive.hhs.gov**
DRIVe questions

**https://www.usajobs.gov/**
Join the team